<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/33083DFE-05A3-4D1E-9EC3-7A9D88542A8C"><gtr:id>33083DFE-05A3-4D1E-9EC3-7A9D88542A8C</gtr:id><gtr:firstName>Ben</gtr:firstName><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK023667%2F1"><gtr:id>1CA59369-7099-499A-99D9-DA2511B0A6DF</gtr:id><gtr:title>Ligand bias at the GLP-1 receptor as a means of favouring cytoprotection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K023667/1</gtr:grantReference><gtr:abstractText>Cell death occurs in many diseases such as type 2 diabetes, Parkinsons disease and Alzheimers disease, and preventing this (&amp;quot;cytoprotection&amp;quot;) might be a useful treatment. A natural hormone called GLP-1 protects cells, but high doses cannot be used because of nausea. It has recently been shown that other molecules similar to GLP-1 tend to be better than others at triggering cytoprotection. In this project I will test a collection of these GLP-1-like molecules for their protective effect.

To do this, I will measure the ability of these molecules to protect cells in a test tube from a high sugar / high fat mix, as is found in the blood of people with diabetes. Using knowledge of the components of each molecule I will identify advantageous features and combine these to find a molecule which is better than those currently available. I will then test whether the difference in cytoprotection is due to their effect on a molecule inside cells called beta-arrestin. Finally, I will investigate whether the most promising molecules can work in living organisms by giving them to mice and seeing if this protects insulin-producing cells from a poison called streptozotocin. If these experiments are successful, the most promising molecules could be developed into drugs to help people with type 2 diabetes and other diseases.</gtr:abstractText><gtr:technicalSummary>One of the key pathophysiological mechanisms in type 2 diabetes is apoptosis of beta cells and consequent failure to secrete insulin. Glucagon-like peptide 1 (GLP-1) prevents apoptosis and therefore holds promise as a cytoprotective therapy, but dosage is limited by nausea. It is now known that beta-arrestin recruitment to the GLP-1 receptor, which mediates the anti-apoptotic response, can be preferentially triggered by different GLP-1 mimetics. A GLP-1 analogue now needs to be identified which optimally stimulates the beta-arrestin pathway in order to enhance its cytoprotective effects. This will be achieved as follows:

1) To determine the optimum peptide sequence for cytoprotection, I will screen a library of synthetic GLP-1-like peptides for ability to rescue MIN6 cells from glucolipotoxic cell death. By correlating sequence with cytoprotection, advantageous sequences will be identified and combined. 2) To confirm the beta-arrestin pathway is responsible for better cytoprotection, I will compare the effect of a small number of peptides on intermediates in the beta-arrestin and other pathways using Western blotting and other in vitro techniques, including in human islets. 3) I will then demonstrate effectiveness in vivo by investigating the ability of promising peptides to protect against streptozotocin-induced beta cell damage in a mouse model.</gtr:technicalSummary><gtr:potentialImpactText>In this project I aim to identify a GLP-1 analogue with exceptional beta cell cytoprotective properties in an animal model of diabetes. Type 2 diabetes is characterised by progressive beta cell death and consequent micro- and macro-vascular complications including amputation, blindness, kidney failure, ischaemic heart diease, and death. Arresting this decline in functioning beta cells with an effective cytoprotective agent would have a major clinical impact on millions of patients with type 2 diabetes worldwide. Once efficacy has been confirmed in vivo, I anticipate early stage clinical trials in humans could begin within 2-4 years. 

Furthermore, GLP-1 has been demonstrated to have a role in cytoprotection in other common disease states, including myocardial infarction, Parkinson's disease, Alzheimer's disease and stroke. This increases the number of patients who could potentially benefit from a GLP-1 agent which is specifically targeted at cytoprotective pathways and away from pathways responsible for side effects.

The wider research community will gain from knowledge obtained in this project. Proof of effectiveness of a GLP-1 analogue in preventing beta cell death in vivo will encourage others to investigate similar agents, in the context of diabetes and also in disparate settings including coronary heart disease and neurodegenerative disease. Researchers not directly focussed on GLP-1 or cytoprotection will benefit from demonstrating how selective targeting using ligand bias can be used to elicit specific physiological responses whilst minimising unwanted effects. 

Furthermore, involvement of the pharmaceutical industry in the UK to aid development of a promising analogue into a successful treatment will have tangible economic benefits, especially given the high worldwide prevalence of diabetes and other conditions in which such an agent might be used. Imperial College London owns the intellectual property rights to the library of GLP-1-like peptides which will be used in this project, and will therefore benefit economically if a promising analogue is taken on by the commercial sector.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>236822</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6421A35E-CA87-4EE3-A3DB-14BB99B278B4</gtr:id><gtr:title>Development of a UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon and dosed GLP-1 from human plasma.</gtr:title><gtr:parentPublicationTitle>Bioanalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e6ec86b3a05ae78f13d31ebd9315435"><gtr:id>9e6ec86b3a05ae78f13d31ebd9315435</gtr:id><gtr:otherNames>Howard JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1757-6180</gtr:issn><gtr:outcomeId>5aa7b0ea39f105.90483991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10DE2BA1-66C1-456E-8752-90DFC86D5DC1</gtr:id><gtr:title>RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc62af1c970f710b6f0b1e5c0bbd1599"><gtr:id>fc62af1c970f710b6f0b1e5c0bbd1599</gtr:id><gtr:otherNames>Cegla J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>5aa7b0ea9f7419.84701073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0B27DFA-CF66-48C0-844A-AE0826EB4B67</gtr:id><gtr:title>Control of insulin secretion by GLP-1.</gtr:title><gtr:parentPublicationTitle>Peptides</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02a692102c18c95a1f2217f9c024bb0c"><gtr:id>02a692102c18c95a1f2217f9c024bb0c</gtr:id><gtr:otherNames>Jones B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0196-9781</gtr:issn><gtr:outcomeId>5aa7b0eaceb3d8.21727685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A70E32C-4F3E-4709-8C3E-4D2F0042A3A0</gtr:id><gtr:title>Potent Prearranged Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor.</gtr:title><gtr:parentPublicationTitle>ChemistryOpen</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/449f3d4a77802528622badac73e37d28"><gtr:id>449f3d4a77802528622badac73e37d28</gtr:id><gtr:otherNames>Jones BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2191-1363</gtr:issn><gtr:outcomeId>5aa7b0ea7545d5.04099931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDA4C0D8-5F6A-4623-9555-F4B940C92900</gtr:id><gtr:title>The New Era of Drug Therapy for Obesity: The Evidence and the Expectations.</gtr:title><gtr:parentPublicationTitle>Drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/449f3d4a77802528622badac73e37d28"><gtr:id>449f3d4a77802528622badac73e37d28</gtr:id><gtr:otherNames>Jones BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-6667</gtr:issn><gtr:outcomeId>56e03f558a4b65.09233873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>137652AC-D09E-4396-B03D-DB2C89482D4C</gtr:id><gtr:title>Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc62af1c970f710b6f0b1e5c0bbd1599"><gtr:id>fc62af1c970f710b6f0b1e5c0bbd1599</gtr:id><gtr:otherNames>Cegla J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>5463c2ed744d81.98917189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4E30B4E-63F3-4D33-9BDA-2F3E5D5E6A08</gtr:id><gtr:title>Allosteric Optical Control of a Class B G-Protein-Coupled Receptor.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a477df8754c6ae6088f89cfa0aa69d6"><gtr:id>6a477df8754c6ae6088f89cfa0aa69d6</gtr:id><gtr:otherNames>Broichhagen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>58c9f592c1a171.69107390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ECC91AC-635E-4890-94A4-1A5E0F790865</gtr:id><gtr:title>A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic ?-Cells.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69101d7cb0af033e3844c306ae3b27f9"><gtr:id>69101d7cb0af033e3844c306ae3b27f9</gtr:id><gtr:otherNames>Buenaventura T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>5aa7b0eb00fc48.51356276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC6FB9FD-5E64-4A20-8D14-0413E6FA828D</gtr:id><gtr:title>Optical Control of Insulin Secretion Using an Incretin Switch.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a477df8754c6ae6088f89cfa0aa69d6"><gtr:id>6a477df8754c6ae6088f89cfa0aa69d6</gtr:id><gtr:otherNames>Broichhagen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>56e03ec1ae9968.90845486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB52B649-2583-4740-A764-3413D5955639</gtr:id><gtr:title>The preanalytical stability of glucagon as measured by liquid chromatography tandem mass spectrometry and two commercially available immunoassays.</gtr:title><gtr:parentPublicationTitle>Annals of clinical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc62af1c970f710b6f0b1e5c0bbd1599"><gtr:id>fc62af1c970f710b6f0b1e5c0bbd1599</gtr:id><gtr:otherNames>Cegla J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0004-5632</gtr:issn><gtr:outcomeId>58c9f5930dd459.96527858</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K023667/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>